Answers are grounded in this paper and cite their sources.
INTRODUCTIONEsophageal cancer ranks seventh in terms of incidence (604,000 new cases) and sixth in overall mortality (544,000 deaths) (1).East part of Turkey has the highest rates of esophageal cancer in the country and forms the bulk of daily oncology practice (2,3).According to the surveillance, epidemiology, and end results (SEER) data, 40% of the cases were diagnosed with the metastatic stage.Even if initially diagnosed as localized disease, the 5-year survival rate is below 50% (4).Chemotherapy (CT) is the standard treatment approach for patients with metastatic esophageal cancer.However, survival rates are low.Primary tumor progression is one of the critical reasons for morbidity and mortality.Aggressive treatment of primary tumor in metastatic patients may contribute to survival.The best evidence for local radiotherapy (RT) for metastatic disease comes from prostate and nasopharyngeal cancer (5-7).We, therefore, examined retrospectively survival outcomes associated with RT ± CT among patients with initially diagnosed AbstractObjective: Chemotherapy (CT) is the standard treatment for patients with metastatic esophageal cancer.Primary tumor progression is one of the important reasons for morbidity and mortality.Several studies have shown that aggressive treatment of primary tumors in metastatic patients may contribute to survival.In this study, patients with metastatic esophageal cancer and who received radiotherapy (RT) to the esophagus were evaluated.Methods: Patients with metastatic esophageal cancer treated with esophageal RT were retrospectively evaluated.ECOG 3-4 patients were not included.Analyzes were performed with SPSS 22.0 (SPSS Inc., IBM Corp., Armonk, NY).Kaplan-Meier, Log-rank, and Cox-regression tests were used for the analysis.Results: Forty-seven patients between 2009 and 2016 were evaluated.The median age was 61 (44-85); 60% of the patients were female.Eighty-nine percent of the histological subtype was squamous cell carcinoma.The mean RT dose was 45 Gy (20-68 Gy).Thirty percent of the patients had concurrent CT.The median overall survival (OS) was 14 months.45 Gy and higher RT doses and concurrent CT were associated with better OS in univariate analysis (p=0.009, p=0.03).The median OS was nine months in patients receiving <45 Gy, and 20 months in patients who received RT ≥45 Gy; 24 months in patients who received concurrent CT, and 13 months in patients who did not.There was no significant prognostic factor in multivariate analysis. Conclusion:Forty-five Gy and higher dose RT with concurrent CT after standard treatment may contribute to survival in metastatic esophageal cancer patients with good performance scores.
No takes yet. Share an insight, caveat, or question.
Turna et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: